Literature DB >> 9570543

An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene.

K W Makar1, C T Pham, M H Dehoff, S M O'Connor, S M Jacobi, V M Holers.   

Abstract

Human CR2 (CD21) is a B lymphocyte protein whose surface expression is restricted primarily to the mature cell stage during development. To study the transcriptional mechanisms that govern cell- and stage-restricted CR2 expression, we first performed transient transfection analysis using constructs extending from -5 kb to +75 bp (-5 kb/+75) in the CR2 promoter. The promoter was found to be broadly active, with no evidence of cell- or stage-specific reporter gene expression. However, the addition of a 2.5-kb intronic gene segment (containing a DNase I hypersensitive site) to the (-5-kb/+75) construct resulted in appropriate reporter gene expression, defined as the silencing of the (-5-kb/+75) promoter activity only in non-CR2-expressing cells. Interestingly, appropriate reporter gene expression required stable transfection of the constructs in cell lines, suggesting nuclear matrix or chromatin interactions may be important for appropriate CR2 gene expression. Importantly, transgenic mice also required the intronic silencer to generate lymphoid tissue-specific reporter gene expression. Some transgenic founder lines did not demonstrate reporter gene expression, however, indicating that additional transcriptional regulatory elements are present in other regions of the CR2 gene. In summary, these data support the hypothesis that human CR2 expression is regulated primarily by an intronic silencer with lineage- and B cell stage-specific activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

2.  A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent.

Authors:  Sabine Maier; Maja Santak; Anja Mantik; Kristina Grabusic; Elisabeth Kremmer; Wolfgang Hammerschmidt; Bettina Kempkes
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma.

Authors:  Kazushi Tanimoto; Yoshihiro Yakushijin; Hiroshi Fujiwara; Masaki Otsuka; Koichi Ohshima; Atsuro Sugita; Akira Sakai; Takaaki Hato; Hitoshi Hasegawa; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2009-04-11       Impact factor: 2.490

Review 4.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

5.  Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA.

Authors:  Heesoon Chang; Yousang Gwack; Dior Kingston; John Souvlis; Xiaozhen Liang; Robert E Means; Ethel Cesarman; Lindsey Hutt-Fletcher; Jae U Jung
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  An alternative promoter of the human neuronal nitric oxide synthase gene is expressed specifically in Leydig cells.

Authors:  Yang Wang; Derek C Newton; Tricia L Miller; Anouk-Martine Teichert; M James Phillips; Michail S Davidoff; Philip A Marsden
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

7.  HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

Authors:  S Moir; A Malaspina; K M Ogwaro; E T Donoghue; C W Hallahan; L A Ehler; S Liu; J Adelsberger; R Lapointe; P Hwu; M Baseler; J M Orenstein; T W Chun; J A Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus.

Authors:  Hui Wu; Susan A Boackle; Punchong Hanvivadhanakul; Daniela Ulgiati; Jennifer M Grossman; Youngho Lee; Nan Shen; Lawrence J Abraham; Timothy R Mercer; Elly Park; Lee A Hebert; Brad H Rovin; Dan J Birmingham; Deh-Ming Chang; Chung Jen Chen; Deborah McCurdy; Humeira M Badsha; Bernard Y H Thong; Hiok H Chng; Frank C Arnett; Daniel J Wallace; C Yung Yu; Bevra H Hahn; Rita M Cantor; Betty P Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-22       Impact factor: 11.205

9.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

10.  Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing.

Authors:  K B Douglas; D C Windels; J Zhao; A V Gadeliya; H Wu; K M Kaufman; J B Harley; J Merrill; R P Kimberly; G S Alarcón; E E Brown; J C Edberg; R Ramsey-Goldman; M Petri; J D Reveille; L M Vilá; P M Gaffney; J A James; K L Moser; M E Alarcón-Riquelme; T J Vyse; G S Gilkeson; C O Jacob; J T Ziegler; C D Langefeld; D Ulgiati; B P Tsao; S A Boackle
Journal:  Genes Immun       Date:  2009-04-23       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.